Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03541525 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Pathophysiological Explorations of Red Blood Cells

Study acronym: GR-Ex
StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

  1. Re-verified, no change to tracked fieldsv6
  2. Study sites: 1 to 25v5
  3. Enrollment target: 1250 to 3750
    • Primary and study completion dates: Oct 10, 2027 to Oct 15, 2037
    • Start date: Oct 10, 2017 to Oct 16, 2017
    v4
  4. Enrollment target: 1000 to 1250v3
  5. Re-verified, no change to tracked fieldsv2
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
GR-Ex is a program labelled by Labex (Laboratory of Excellence) by the French Ministry of Higher Education and Research. This program aims to develop the means to improve knowledge in the physiology and pathologies of erythropoiesis, red blood cells and iron metabolism, and to develop new therapeutic protocols capable of providing added value in terms of innovation.
Trial Details
NCT Number NCT03541525
Lead Sponsor Imagine Institute
Conditions
(from sponsor)		 Red Blood Cell Disorder
Enrollment 3,750 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov